Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA, obstructive sleep apnea
FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.
FDA approves Zepbound for obstructive sleep apnea
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep apnea.
F.D.A. Approves Weight Loss Drug to Treat Obstructive Sleep Apnea
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder.
FDA approves Zepbound for sleep apnea in patients with obesity
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.
Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to severe OSA in people with obesity.
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.
FDA approves Zepbound as a treatment for obstructive sleep apnea
Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and Drug Administration has appro
FDA approves weight loss drug Zepbound to treat obstructive sleep apnea
The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
USA Today
5d
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
Zepbound is the first medication approved to treat patients with
obstructive
sleep
apnea
, said Sally Seymour, the FDA's director of the division of pulmonology, allergy and critical care.
SchaeffersResearch.com
3d
2 Sleep Apnea Stocks in Focus Today
The FDA approved Eli Lilly's (LLY) obesity drug for the treatment of sleep apnea, sending rival ResMed (RMD) stock lower ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
'Baby Driver' actor dies
Man dies after saving family
Corrections officer dies
Christmas Eve attack arrest
Body found in wheel well
Pakistani airstrikes on AFG
Escaped murderer captured
HEARTS Act signed into law
Former Eagles LB dies at 79
Vows more weapons to UKR
Official national bird of US
Taxi hits pedestrians in NYC
Phoenix airport shooting
Ambassador to Panama
Suriname ex-president dies
Kazakhstan plane crash
Russia arrests four suspects
Taiwan blocks $950M deal
ISR strike kills journalists
Hit by cyberattack
Teases 'Happy Gilmore 2'
Breaks QB rushing record
Holiday retail sales rise
Bird flu at Wash. sanctuary
Pet food recalled
Music producer Perry dies
Calls for peace in Ukraine
Eye drops recalled
NC man charged w/ murder
Iran restores access
Discharged from hospital
To honor 3 NFL assistants
Related topics
Zepbound
Eli Lilly
Tirzepatide
Food and Drug Administration
Feedback